

Adcock Ingram IS PROUD TO PRESENT

REMSIMA *Aid*

REMSIMA SUPPORT MADE 4 U

Offering all patients
on REMSIMA® the benefit
of a professional patient
support team



Reimbursement
application and
support



HCP
Feedback

- Reimbursement status
- Highlights from patient interaction
- Overview of patient activity



Infusion
support

- Coordinating infusion appointments
- Ensuring script is matched to infusion appointment
- Confirmation with patient on infusion arrangements
- Post infusion support



Nurse-driven
patient support
and education

- Reimbursement specific
- Treatment specific
- Disease specific

0861ADCOBIO (0861232624)
remsima@pharmacallcc.com

adcock Ingram

ENROLMENT OF A NEW PATIENT

1



Specialist decides patient is eligible for treatment and informs patient of PSP.
Consent signed

2



Patient gives consent and enrolls in program. Patient is profiled for support by the program based on needs

3



Specialist rooms compiles reimbursement motivation. RemAid program team available to provide support

Specialist submits motivation to SAGES/SARAA for biologic approval



Program manages reimbursement motivations on behalf of patient

4



SAGES/SARAA: Approved recommendation for treatment submitted to Funder



Program submits motivation to funder and tracks approvals and re-motivation on behalf of patient

Program provides educational support to patient on disease and therapy expectations.

Frequency and channel of communication dependent on patient needs

5



Program provides feedback to patient's referring HCPs on patient status

Program provides feedback to specialist & nurses on PSP patient interactions & motivation status

Program provides scheduling support for patient infusions

Reporting and management of AE's to Adcock Ingram Pharmacovigilance department

6



Specialist manages patient disease and treatment



[S4] REMSIMA® powder for concentrate for solution for infusion. Each vial contains: 100 mg infliximab. Reg. No. 52/30.1/0309. For full prescribing information refer to the package insert approved by the medicines regulatory authority, Adcock Ingram Limited. Reg. No. 1949/034385/06. Private Bag X69, Bryanston, 2021. Tel. + 27 11 635 0000. www.adcock.com 202006291042179



You have subscribed to receive digital communication from Adcock Ingram.
Should you no longer wish to receive digital communication, please reply with OPT-OUT/UNSUBSCRIBE

To report an Adverse Event, e-mail Adcock.AEReports@adcock.com or call 011 635 0134.
To request a copy of the current approved package insert or references, e-mail: Helpdesk.MedicalAffairs@adcock.com

Disclaimer: This material was presented in digital format, it is not intended for copying or distribution and remains the propriety property of Adcock Ingram.